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Abstract
Background: Countries worldwide recommend women planning pregnancy to use daily 400 mg of synthetic folic acid in the
periconceptional period to prevent birth defects in children. The underlying mechanisms of this preventive effect are not
clear, however, epigenetic modulation of growth processes by folic acid is hypothesized. Here, we investigated whether
periconceptional maternal folic acid use and markers of global DNA methylation potential (S-adenosylmethionine and S-
adenosylhomocysteine blood levels) in mothers and children affect methylation of the insulin-like growth factor 2 gene
differentially methylation region (IGF2 DMR) in the child. Moreover, we tested whether the methylation of the IGF2 DMR was
independently associated with birth weight.
Methodology/Principal Findings: IGF2 DMR methylation in 120 children aged 17 months (SD 0.3) of whom 86 mothers had
used and 34 had not used folic acid periconceptionally were studied. Methylation was measured of 5 CpG dinucleotides
covering the DMR using a mass spectrometry-based method. Children of mother who used folic acid had a 4.5% higher
methylation of the IGF2 DMR than children who were not exposed to folic acid (49.5% vs. 47.4%; p = 0.014). IGF2 DMR
methylation of the children also was associated with the S-adenosylmethionine blood level of the mother but not of the
child (+1.7% methylation per SD S-adenosylmethionine; p = 0.037). Finally, we observed an inverse independent association
between IGF2 DMR methylation and birth weight (21.7% methylation per SD birthweight; p = 0.034).
Conclusions: Periconceptional folic acid use is associated with epigenetic changes in IGF2 in the child that may affect
intrauterine programming of growth and development with consequences for health and disease throughout life. These
results indicate plasticity of IGF2 methylation by periconceptional folic acid use.
Citation: Steegers-Theunissen RP, Obermann-Borst SA, Kremer D, Lindemans J, Siebel C, et al. (2009) Periconceptional Maternal Folic Acid Use of 400 mg per Day
Is Related to Increased Methylation of the IGF2 Gene in the Very Young Child. PLoS ONE 4(11): e7845. doi:10.1371/journal.pone.0007845
Editor: Cuilin Zhang, National Institute of Child Health and Human Development/National Institutes of Health, United States of America
Received June 2, 2009; Accepted October 16, 2009; Published November 16, 2009
Copyright:  2009 Steegers-Theunissen et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which
permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the Netherlands Heart Foundation (2002B027 and 2006B083), The Corporate Development International (2005), The
Netherlands Organization for Scientific Research NWO (911-03-016) and the EU funded Network of Excellence LifeSpan (FP6 036894). The funders had no role in
study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: r.steegers@erasmusmc.nl
Introduction
Every year around 8 million children are born with a serious
birth defect worldwide. Folate deficiency during conception up to
the third month of gestation, i.e., periconceptional period, is an
etiological factor in several birth defects. Randomized controlled
trials have shown that periconceptional synthetic folic acid use
prevents neural tube defects [1]. For that reason periconceptional
folic acid in a dose of 400 mg per day has been promoted to all
women planning pregnancy [2].
Over the last decade, several campaigns were started to improve
the awareness of the importance of periconceptional use of
synthetic folic acid in tablets. Furthermore, folic acid fortification
of food has been introduced in the US, Canada and Chile [3].
Since the implementation of these measures, a significant decrease
in birth rates of neural tube defects, orofacial clefts, congenital
heart defects and diaphragmatic hernia has been reported
[4,5,6,7]. However, periconceptional folic acid use has also been
reported to have adverse effects including an elevated risk of
pyloric stenosis, obstructive urinary tract defects, obesity, insulin
resistance and colon cancer [7,8,9].
The mechanisms underlying the beneficial and adverse effects of
periconceptional folic acid use are largely unclear. Following
current thinking about the developmental origins of health and
disease, an altered epigenetic regulation of growth processes
induced by periconceptional folic acid may contribute to both the
immediate effects and chronic disease associations in later life
[10,11]. Epigenetic regulation determines the potential of a
genomic region to become transcribed [12]. The best understood
epigenetic mechanism is the methylation of cytosine-guanine
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(CpG) dinucleotides in the DNA of mammals. Methyl donors,
including folic acid, are required to establish and maintain DNA
methylation. Methyl groups for DNA methylation reactions are
supplied by demethylating the activated form of methionine into
S-adenosylmethionine (SAM), to form S-adenosylhomocysteine
(SAH) and homocysteine. In agreement with their crucial role in
methylation reactions, in human SAM and SAH plasma levels and
the SAM/SAH ratio are frequently used markers of global DNA
methylation potential [13,14].
Direct evidence that the availability of methyl donors during
gestation is required to establish and maintain DNA methylation
patterns comes from experiments in the yellow Avy agouti mice [15].
Supplementing the diet of pregnant dams with methyl donors,
including folic acid, results in silencing of the agouti gene due to
DNA methylation resulting in offspring with a mainly brown coat
colour and a lower tendency for obesity, cancer and diabetes. We
recently observed that similar mechanisms may play a role in
humans. Periconceptional exposure to famine during the Dutch
Famine at the end of WWII was associated with a persistently
lower methylation of the maternally imprinted insulin-like growth
factor 2 (IGF2) gene [16]. IGF2 is an embryonic growth factor that
is expressed in most tissues and regulated in rats by periconcep-
tional nutrient intake [17]. Complete loss of methylation at the
IGF2 differentially methylated region (DMR) results in biallelic
expression of IGF2 and is associated with an increased risk of
colorectal adenoma [18]. IGF2 imprinting defects also underlie
Beckwith-Wiedemann syndrome which is characterized by
overgrowth [19]. Here, we hypothesize that periconceptional folic
acid use by the mother may have consequences for IGF2 DMR
methylation of the child with a subsequent effect on intrauterine
growth as reflected in birth weight.
Results
The quantitative traits, including birth weight and the
biochemical markers of global DNA methylation and folate, were
similar according to periconceptional folic acid use for both
mothers and children (table 1). The relative methylation of the
IGF2 DMR was 4.5% higher in folic acid exposed children as
compared with non exposed children (absolute methylation 0.495
(SE 0.004) vs. 0.474 (0.007); p = 0.014, table 2. In the linear mixed
model analysis additionally adjustment for maternal education
level revealed an adjusted p-value of 0.009, table 3. Higher levels
of methylation were also observed for individual CpG dinucleo-
tides comprising the IGF2 DMR, particularly for CpG #4,
although not always significantly.
Next, we tested the association of other variables in mother and
child with IGF2 DMR methylation in children (table 3). In
addition to periconceptional maternal folic acid use, a higher
maternal SAM concentration, but not that of the child, was
associated with a higher IGF2 methylation in the child (p = 0.037).
This association remained significant after additional adjustment
for maternal education and the SAM concentration of the child
(padjusted = 0.047).
To test for a possible phenotypic consequence of changes in
IGF2 methylation, we analyzed the relationship with birth weight.
A 1.7% higher IGF2 methylation in the child was associated with
one SD decrease in birth weight of 584 grams (p = 0.034), which
was independent of periconceptional exposure to folic acid and
gestational age at delivery (padjusted = 0.041).
Discussion
The key finding of our study is that periconceptional folic acid
use of the mother is related to an increased methylation of the
IGF2 DMR of the child. The reported stability of IGF2 DMR
methylation up to middle age [20,21] supports the interpretation
that the IGF2 methylation changes we observed are explained by
periconceptional folic acid exposure. The difference in DNA
methylation associated with folic acid exposure is remarkably
similar to our previous observation of a 5.2% reduced IGF2
methylation after periconceptional exposure to famine [18]. The
opposite direction of the associations suggests that the availability
of methyl donors during the periconceptional period may affect
IGF2 DMR methylation. We further hypothesized that changes in
IGF2 DMR methylation would influence intrauterine growth. Our
Table 1. Quantitative traits according to maternal periconceptional folic acid use.
Mothers Children
No Folic Acid
(n=34)
Yes Folic Acid
(n =86) P-value
No Folic Acid
(n=34)
Yes Folic Acid
(n =86) P-value
Male, n (%) - - 20 (59%) 50 (58%) 0.945
Age, years 32.6 (0.8) 32.2 (0.4) 0.624 - - -
Age, months - - - 17.1 (0.5) 17.3 (0.2) 0.709
Birth weight, grams - - - 3363 (98) 3490 (64) 0.287
Gestational age, weeks - - - 39.4 (0.3) 39.7 (0.2) 0.496
Biochemistry
SAM, mmol/L 79.9 (2.5) 80.2 (1.3) 0.897 102.7(3.3) 106.4 (2.1) 0.363
SAH, mmol/L 15.0 (0.6) 14.5 (0.3) 0.438 18.5 (1.0) 17.3 (0.5) 0.278
SAM/SAH 5.5 (0.2) 5.7 (0.1) 0.357 6.1 (0.4) 6.6 (0.2) 0.267
Folate, nmol/L
serum 15.3 (0.9) 17.8 (1.2) 0.189 31.5 (2.5) 32.1 (1.6) 0.748
red blood 687 (70) 720 (30) 0.589 973 (72) 1064 (41) 0.245
Data are presented in numbers (percentages) and mean (standard error).
Abbreviations: SAM, S-adenosylmethionine; SAH, S-adenosylhomocysteine.
doi:10.1371/journal.pone.0007845.t001
Folate and IGF2-Methylation
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study indeed indicated an association between IGF2 DMR
methylation and birth weight as surrogate for intrauterine growth,
but not between periconceptional folic acid use and birth weight.
Compared to our findings in humans, the size of the effects on
DNA methylation of prenatal exposures have found to be
comparable in sheep but are larger in rodents [22,23,24]. In this
comparison we have to emphasize that human populations are
inevitably more heterogeneous than the inbred rodents kept at the
same, well-controlled environmental conditions. The different
effects in animal studies can also be due to the common use of a
combined intervention consisting of multiple methyl donors and/
or protein deficiency instead of folic acid only. Lastly, the larger
effects in rodents are shown in other tissues than in blood, which
are not readily accessible from human study subjects.
In addition, our study indicated an association between higher
IGF2 methylation and lower birth weight. This inverse association
is compatible with a relative intrauterine silencing of the
embryonic growth factor IGF2 resulting in reduced growth
[25,26]. This links our data to the finding that IGF2 loss of
imprinting leads to somatic overgrowth (Beckwith-Wiedemann
syndrome) [27] and possibly colorectal cancer [20] although we
cannot exclude the explanation that the change in IGF2
methylation marks possible greater changes elsewhere in the
genome that underlie the association observed. Periconceptional
folic acid use may contribute to the restoration of a loss of
imprinting. It remains to be established whether DNA methylation
changes contribute to the adverse effects reported for periconcep-
tional folic acid use [7,8,9,28]. Studies are required to establish
optimal timing, dose and type (natural folate or synthetic folic acid)
to prevent birth defects and at the same time minimize adverse
effects later in life.
From this study reveals that periconceptional folic acid use is
associated with epigenetic changes in IGF2. However, in contrast
with large mother-child cohorts, we did not find a positive
association between periconceptional folic acid use and higher
birth weight [29,30]. It is known that women using periconcep-
tional folic acid supplements are generally more health conscious
and higher educated. Furthermore, the women exposed to the
Dutch famine were not only deprived of folate, but also of other
essential macro- and micronutrients that serve as methyldonors,
e.g., methionine. Thus, it should be emphasized that many factors
together including other genes besides periconceptional folic acid
contribute to birth weight. This may explain the absent association
between periconceptional folic acid use and birth weight in our
study.
Periconceptional use of folic acid did not affect average levels of
the biomarkers SAM, SAH or SAM/SAH measured at 17 months
in the mother and in the child. However, we found a significant
correlation between the maternal SAM concentration at the study
moment and IGF2 methylation of the child. The developmental
hypothesis of health and disease states that periconceptional
exposures may affect metabolic imprinting of the child. This is in
line with our finding that periconceptional folic acid use can affect
the metabolic imprinting of the methylation pathway of the child.
Of note, this association was not influenced by fortification of food
with folic acid which is absent in The Netherlands, UK and other
European countries, which may have strengthened the observed
associations.
Although we did not measure levels of biomarkers of methylation
in the periconception period, their levels will have been compar-
able to those we measured 17 months after delivery. This is
substantiated by Nurk et al. showing that the biomarkers of
methylation show a limited variability in the periconception period
and over a subsequent period of 1–2 years [31]. Furthermore, there
are no substantial differences in preconceptional maternal dietary
habits and lifestyles and those 1 to 1.5 year post partum which affect
these biomarkers [32].
A limitation of both our study and others is that they relied on
genomic DNA extracted from whole blood so that heterogeneity in
cell populations may have contributed to the outcomes [18]. Our
study likely is less sensitive to such heterogeneity because the
epigenetic state of imprinted loci is less dependent on cell
differentiation and, importantly, a previous study showed that
when demethylation of IGF2 DMR was observed in peripheral
blood lymphocytes of an individual, this was also found in colon
tissue [20], which has a distinct embryologic origin (endoderm and
mesoderm, respectively). The finding that the common epigenetic
variation in IGF2 DMR might influence birth weight is intriguing
but should be interpreted with care because the sample size was
relatively small and other (non)genetic factors are also involved. It
is currently unknown whether modestly increased IGF2 DMR
methylation upregulates IGF2 expression. Furthermore, it has not
been established whether such quantitative differences measured
in lymphocytes mark a soma-wide phenomenon as was suggested
Table 2. IGF2 DMR methylation in the child according to
maternal periconceptional folic acid use of 400 mg per day.
No Folic Acid
(n=34)
Yes Folic Acid
(n =86) P-value
Complete DMR 0.474 (0.007) 0.495 (0.004) 0.014
CpG #1 0.473 (0.009) 0.484 (0.005) 0.292
CpG #2&3 0.334 (0.006) 0.348 (0.004) 0.059
CpG #4 0.590 (0.016) 0.632 (0.010) 0.023
CpG #5 0.511 (0.011) 0.516 (0.080) 0.602
Linear Mixed Model analysis. Independent absolute methylation of the CpG
dinucleotides without adjustments is presented in mean and (standard error).
doi:10.1371/journal.pone.0007845.t002
Table 3. IGF2 DMR methylation in the child and independent
factors of the mother and the child.
Factors Mother P-value Child P-value
Folic acid use +4.5% (1.8) 0.014 - -
Female sex - - +2.0% (1.6) 0.232
Age 20.4% (0.8) 0.585 20.7% (1.0) 0.478
Birth weight - - 21.7% (0.8) 0.034
Gestational age - - 20.9% (0.8) 0.276
Biochemistry
SAM, mmol/L +1.7% (0.8) 0.037 +1.2% (0.8) 0.129
SAH, mmol/L +0.8% (0.8) 0.331 +0.1% (0.8) 0.882
SAM/SAH +0.0% (0.8) 0.985 +0.3% (0.8) 0.717
Linear Mixed Model analysis. Data are presented in percentage (standard error)
of mean change in relative methylation. For independent quantitative
parameters the change in relative methylation is given per SD-change in that
parameter. The p-value of the significant association of periconceptional folic
acid use and IGF2 DMR methylation was additionally adjusted for maternal
education. The p-value for the significant association between maternal SAM
and IGF2 DMR methylation was also adjusted for maternal education and the
SAM concentration of the child. The p-value for the significant association
between IGF2 DMR methylation and birth weight was additionally adjusted for
periconceptional folic acid use and gestational age at delivery.
doi:10.1371/journal.pone.0007845.t003
Folate and IGF2-Methylation
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for loss-of-imprinting of the IGF2 DMR [20]. Therefore, in future
human studies the sampling of different tissues should be
performed.
Our study provides the first evidence that periconceptional folic
acid use may be related to DNA methylation in the child.
Moreover, such DNA methylation changes may have phenotypic
consequences as illustrated by the association between higher IGF2
methylation and decreased birth weight. A simple preventive
strategy as periconceptional folic acid use may affect epigenetic
control and as such may link the prevention of intrauterine
development, i.e., birth defects such as neural tube defects, and
growth due to a loss of imprinting with the risk of chronic diseases
in these children throughout life. It has to be established how folic
acid intake affects the epigenetic regulation of sets of relevant
genes and whether adverse effects are to be expected from an
altered methylation at such loci. Given the ongoing exposure it is
timely to monitor the (long term) effect on DNA methylation also
of other lifestyles and environmental influences, such as overnu-
trition, fortification of food, smoking, stress and the use of assisted
reproductive techniques.
Methods
Ethics statements
The study protocol was approved by the Central Committee for
Human Research (CCMO) in The Hague, The Netherlands, and
the Medical Ethical and Institutional Review Board of the
Erasmus MC, University Medical Center in Rotterdam, The
Netherlands. All mothers gave their written informed consent and
mothers and their partner on behalf of their participating child.
Study design and population
In a cross-sectional study mothers and children between 12 and
18 months of age were enrolled via public health centers in
Rotterdam, the Netherlands between October 2003 and January
2007. The Dutch health care system includes a standardized and
regular check up of all newborns for health, growth and
development by physicians trained in child health care. Children
were eligible as controls if they did not have a major congenital
malformation or chromosomal defect according to the medical
records from the regular check up at the child health center. These
mothers and their healthy nonmalformed child served as controls
in the previously described HAVEN-study [33,34]. Mothers and
children were studied at the standardized study moment of around
17 months after delivery of the index child, at which both blood
samples for DNA methylation and folate in serum and red blood
cells of the child and questionnaire data via the mother on
periconceptional exposures, such as folic acid use, were obtained.
For 186 mother-child pairs biomarkers of global methylation and
blood samples for DNA methylation and folate in serum and red
blood cells were available. Because we aimed to show an effect of
periconceptional folic acid use, in particular an extreme effect, the
48 mothers who used partially folic acid during this period were
excluded. 40 Mothers had completely refrained from periconcep-
tion folic acid use and 98 reported the use of folic acid according to
the Dutch recommendation of a daily intake of a folic acid
containing preparation of 400 mg from at least 4 weeks before until
8 weeks after conception. Six mother-child pairs of whom the
mother had not used folic acid were excluded because insufficient
genomic DNA was available of the child for bisulfite treatment
resulting in 34 unexposed mother-children pairs eligible for the
current epigenetic study. For technical reasons 86 mother-child
pairs were randomly selected from the exposed group, so that the
total number of mothers and children studies was 120.
The questionnaires providing information on general traits, folic
acid use and birth weight filled out by the mother at home were
checked for completeness and consistency at the hospital visit
during the standardized study moment by the researcher. We
extracted data on maternal age and folic acid use, and age, gender,
birth weight and gestational age at delivery of the child.
The standardization of the blood sampling, plasma handling,
extraction of genomic DNA and measurement of SAM, SAH and
folate were described previously and are reported as control data
in the comparison of cases with a congenital heart defect [33,34].
DNA Methylation
DNA methylation measurements were performed on genomic
DNA extracted from whole blood samples obtained from the
children. Bisulphite treatment was carried out on 0.5 mg genomic
DNA using the EZ 96-DNA methylation kit (Zymo Research).
The 120 samples were blinded as to exposure status and split into
two equal groups with a similar distribution in exposure status thus
preventing possible batch effects. Subsequently, to assess IGF2
DMR methylation 5 CpG dinucleotides of the IGF2 DMR
(chr11:2,126,035-2,126,372 in NCBI build 36.1) was measured in
triplicate using a mass spectrometry-based method (Epityper,
Sequenom)[20]. The quantitative accuracy and concordance with
clonal polymerase chain reaction bisulphite sequencing is well-
established [21]. Two CpG dinucleotides confounded by SNPs
were discarded so that the current study reports on CpG
dinucleotides located at positions 41 (CpG #1),57 and 60
(#2&3; adjacent CpGs that could not be resolved individually,
202 (#4) and 251 (#5) bp in the amplicon targeting the IGF2
DMR.
Statistical analyses
Differences in quantitative traits in mothers and in children
according to maternal periconception folic acid use were tested
using an independent t-test. Differences in gender distribution
were tested using a chi-square test. IGF2 DMR methylation was
assessed by measuring multiple CpG sites that are correlated [21].
Raw methylation data can still be used (instead of for example
averaging over the various CpG dinucleotides that differ in DNA
methylation level) by applying linear mixed models. Linear mixed
models may be viewed as an extension of a t-test that accounts for
the correlation between methylation of CpG dinucleotides and
methylation data missing at random [16,18]. When applied to the
analysis of single CpG dinucleotides without adjustment for
covariates, a linear mixed model and a t-test yield identical results.
For the analysis of the complete IGF2 DMR, methylation data all
CpG dinucleotides were entered in the model with the study
subject identifier as a random effect to account for the correlation
between CpG dinucleotides. The CpG dinucleotide identifier, the
exposure status and other traits (e.g., SAM concentration or birth
weight) or covariates (e.g., bisulfite plate) were entered as fixed
effects. When testing single CpG dinucleotides, the study subject
and CpG nucleotide identifiers were removed from the linear
mixed model. Before testing independent associations of quanti-
tative traits with IGF2 DMR methylation, Z-scores were calculated
so that the resulting estimated effect size indicates the methylation
change per standard deviation (SD) change in the parameter
tested. Z-score does not affect a variable otherwise than
standardising the mean to 0 and the SD to 1 and assists in
interpreting the results.
The p-value of the significant association of periconceptional
folic acid use and IGF2 DMR methylation was additionally
adjusted for maternal education. The p-value for the significant
association between maternal SAM and IGF2 DMR methylation
Folate and IGF2-Methylation
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was also adjusted for maternal education and the SAM
concentration of the child. The p-value for the significant
association between IGF2 DMR methylation and birth weight
was additionally adjusted for periconceptional folic acid use and
gestational age at delivery. All p-vales were two-sided and all
statistical analyses were performed using SPSS 16.0.
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